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Abstract
Background:  The inactivation of the tumour suppressor gene and activation of the proto-
oncogene are the key steps in the development of the human cancer. The p53 and c-erbB-2 are
the best examples of it. In the present study, our aim was to determine the role of these genes in
the carcinogenesis of gallbladder by immunohistochemistry.
Methods: In all 78 consecutive patients of gall bladder diseases were studied for p53 and c-erbB-
2 expression immunohistochemically and their expression was correlated with the age, grades and
stages of the disease and presence of stone. An informed consent was obtained in each case. Chi
square and z test were applied to see the association of p53 and c-erbB-2 over expression with
other clinicopathological factors.
Results: Eight (20%) patients of gall bladder cancer were positive for p53 expression and 10 (25%)
patients for c-erbB-2. The p53 positivity increased with increasing grade while cerbB-2 positivity
decreased with increasing grade of gall bladder cancer. Mean age in cerbB-2 positive cases were
lesser as compared to negative cases while p53 did not show such association with age.
Conclusion: Only one case of gall bladder cancer co-expressed the p53 and c-erbB-2, thereby
suggesting that p53 and c-erbB-2 may have independent role in carcinogenesis of gall bladder
cancer. c-erbB-2 over expression in adenoma and younger age group indicates its role as an early
event in carcinogenesis of gallbladder. However study of larger sample is required to further
validate the results.
Background
Gallbladder cancer (GBC) is a latent disease, as a result it
is usually diagnosed in an advanced stage, resulting a 5
year survival rate of <10% [1]. Gallbladder cancer is very
common in South American countries, the Mediterranean
region, Japan [2] and northern part of India [3]. Chile has
the highest incidence rate of GBC (7.5/100,000 popula-
tion) especially among American Indian females [4].
According to Indian Council of Medical Research cancer
registry 2001 [5], in North India the incidence of GBC is
2.5–8.9/1,00,000 female and 1.6 3.7/1,00,000 male
whereas in Southern India it is only 0.7–0.8/1,00,000
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female and 0.50.6/1,00,000 male population. The poor
prognosis and high incidence of GBC in North India
necessitates a closer look at the molecular changes for
evolving an effective early diagnostic and therapeutic
strategy. The p53 gene, the "guardian of the genome" a
tumour suppressor gene, is the basic genetic alteration in
GBC [6]. A key feature of p53 is its tendency to remain
"latent" in unperturbed cells. In contrast to the normal
p53 gene product (protein), the mutated p53 gene prod-
uct (protein) tends to accumulate in cell nuclei which can
be detected by immunohistochemistry [7].
The second most common genetic change occurs is c-
erbB-2, a proto-oncogene also known as neu or HER-2.
HER-2 glycoprotein consist of extracellular and a cytoplas-
mic domain. The cytoplasmic domain has activating
phosphorylation and transcription initiating function and
it is the domain to which antibodies for immunohisto-
chemical studies have been derived [8]. Alterations in
cerbB-2 signalling have been implicated in neoplastic
transformation of cells in vitro [9] and neoplasia in both
experimental animals and human [10], however few stud-
ies have investigated the role of c-erbB-2 in human gall
bladder cancer [11-14]. Over expression of c-erbB-2 indi-
cates the worse prognosis [11,15].
A composite report on both p53 and c-erbB-2 in gallblad-
der cancer (GBC) in India is sparse. Therefore we have
undertaken this pilot study to screen the GBC patient for
both p53 and c-erbB-2 in this high prevalence area for
GBC.
Methods
The study was carried out by the Department of Surgical
Oncology, Institute of Medical Sciences, Banaras Hindu
University, Varanasi, India and patients from the said
department formed the basis of the present research. His-
topathology and immunohistochemistry of the gallblad-
der specimens were carried out at the UGC advanced
Immunodiagnostic Training and Research Centre, Depart-
ment of Pathology. The Institutes' Ethics Committee
approved the study. An informed consent was obtained
from each patient. Clinical details were recorded on pre-
formed proforma in each case.
A total of 78 consecutive patients between October 2003
and May 2004, including 40 GBC, 10 adenoma, 5 carci-
noma in situ, and 23 gallstone disease (GSD) were exam-
ined for p53 and c-erbB-2 immunohistochemically.
The surgically resected specimens of gallbladder cancer
were fixed in 10% buffered formalin and embedded in
paraffin. The cut sections were stained with haematoxylin
and eosin (H&E). The diagnosis of GBC was based on
clinical suspicion and histopathological confirmation in
each patient. Depth of invasion and staging were judged
using TNM classification by American Joint Committee in
the year 2002 [16]. Histopathological grading of GBC was
done according to WHO classifications [17].
The p53 and c-erbB-2 expression were examined by the
immunohistochemical methods as given below-
Three to five micron thick sections were cut from the par-
affin embedded tissue blocks and placed on gelatin coated
slides. Immunohistochemical staining of p53 and c-erbB-
2 was performed using Avidin Biotin method. Instruc-
tions of kits (Novacastra laboratories Ltd., UK.) were fol-
lowed. Brief description of technique is as follows:
The sections were dewaxed in xylene and rehydrated in
graded alcohol. Sections were then immersed in 1.5%
H2O2 in methanol for 10 minutes followed by washing
in tap water. Nonspecific binding was blocked by incubat-
ing the slide with normal rabbit sera for 10 minutes.
Excess serum was shaken then sections were immediately
covered with primary antibodies (ready to use) and incu-
bated for 30 minutes in humid chamber.
The primary antibody used for p53 was NCL-p53 clone
DO-7 and for c-erbB-2 detection NCL-c-erbB-2 clone CB
11 antibody. After washing in tris buffer saline (pH 7.6),
secondary biotinylated antibody (rabbit anti mouse IgG
with 1 in 50 dilution in TBS) was put for one hour. The
slides were washed with different changes of TBS for 10
minutes. Then the slides were incubated with ABC reagent
using 100 µl TBS, 1 µl avidin and 1 µl Biotin for 30 min-
utes. The colour was developed by using diamino benzi-
dine (DAB) as the chromogen and slides were washed
well with tap water. Finally the slides were counter stained
with Mayer's haematoxylin for 2 minutes, washed, dried
in alcohol and mounted with DPX mountant. Sections of
carcinoma breast were taken as positive control slide for
both p53 and c-erbB-2 staining.
Criteria of positive immunohistochemical staining
The results were evaluated quantitatively as well as quali-
tatively according to intensity of staining pattern. Accord-
ing to the estimated number of positive cells they were
divided into five groups [18] (- = <10 %, +1 = 10–30 % of
cells positive, +2 = 30–50 % of cells positive, +3 = >50%
of cells positive). The p53 and c-erbB-2 immunoreactivity
were considered positive when more than 10% nuclei and
membrane bound or cytoplasmic staining was observed
respectively [19]. Cytoplasmic staining for p53 was disre-
garded. The intensity of staining was graded as weak,
moderate and strong.BMC Cancer 2006, 6:126 http://www.biomedcentral.com/1471-2407/6/126
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Statistical analysis
Statistical analysis of the data was done on SPSS computer
statistics programme. To determine the association
between two or more than two variables, chi square test
has been applied.
Results
The mean age of GBC patients was 53.62 ± 12.46 with age
range of 30 to 70 years and female to male ratio was 3:1
while the mean age of GSD patient was 48.29 ± 14.56
years with age range of 28 to 58 years and female to male
ratio was 2.5:1. The p53 over expression was found in 8
out of 40 (20%) cases of gallbladder cancer but in none of
the benign diseases of gallbladder (Table 1). Amongst the
patients of GBC none of the grade I cases over expressed
p53, while 2/10 (20%) and 6/16 (37%) of grade II and III
cases revealed over expression respectively. The immuno-
reactivity was mainly nuclear with only occasional cyto-
plasmic staining (Figure 1). Cells having invasive
character showed intense nuclear p53 positivity (Figure
1b and 1c). No correlation (p = NS) of p53 positivity with
the clinical stage was observed (Table 2). However there is
statistically significant (p < 0.05) difference in p53 over
expression pattern among grades of tumour (Table 3).
Only ten out of 40 cases of GBC (25%) over expressed c-
erbB-2 (Table 1). In relation to the grade of tumour 35%
grade I (Figure 2b &2d), 30% of grade II (Figure 2a) and
12% of grade III (Figure 2c) GBC cases revealed c-erbB-2
over expression. Four of the 10 (40%) papillary adenoma
of the gallbladder over expressed c-erbB-2 (Table 1). None
of the Carcinoma in situ or GSD stained positive. Only 6
cases of GBC showed more than 40% cells with positive
staining for c-erbB-2. A strong c-erbB-2 over expression
was present in papillary adenocarcinoma (Figure 3a &2b).
This intense staining was predominately seen in apical
surfaces of the papillary epithelium and luminal surfaces
of the glands. One papillary adenoma showed apical
granular positivity (Figure 3b), and the second one
showed intense membranous staining. In grade III adeno-
carcinoma cases, no membranous pattern of staining were
observed, only cell clumps showed cytoplasmic staining
(Figure 2c). There is no statistical difference in cerbB-2
over expression among stages of gallbladder tumour
(Table 4). Likewise comparison of c-erbB-2 over expres-
sion pattern among grades of tumour revealed non signif-
icant (p = NS) difference although higher c-erbB-2 over
expression was noted in low grade tumour (Table 5).
We found over expression of both p53 and c-erbB-2 in
only one case in our study. There was statistically no sig-
nificant difference in expression pattern of p53 and c-
erbB-2 among different histological groups (p = NS)
except in adenoma where only c-erbB-2 is positively
expressed.
There was a significant (p < 0.05) association between p53
over expression and gallbladder cancer with stone. How-
ever c-erbB-2 over expression did not show significant
association with gallstone although higher cerbB-2 posi-
tivity was noted in gallbladder cancer with associated gall-
stone. There was no significant correlation of p53
positivity with age and sex of the patients. Interestingly
the c-erbB-2 positive cases were in mean age of 37 years as
compared to 48 years for c-erbB-2 negative cases.
Discussion
Cancer arises mainly from mutations in somatic cell.
However it is not the result of a single mutation rather it
Photomicrograph showing all p53 staining Figure 1
Photomicrograph showing all p53 staining. (1a) nuclear p53 
positivity in well differentiated adenocarcinoma; (1b and c) in 
invasive high grade adenocarcinoma; (1d) strong positivity in 
moderately differentiated adenocarcinoma
Table 1: Comparison of C-erbB-2 and p53 expression in different histological Groups Z value test.
Patient Group Total Cases P53 expression c-erbB-2 expression Z value P value
No. % No. %
1. Non-malignant gallbladder disease 23 0 0 0 0 0
2. Adenoma 10 0 0 4 40 2.58 <0.05
3. Carcinoma in situ 5 0 0 0 0 0
4. Gall bladder cancer (Histological grade) 40 8 20 10 25 0.730 NSBMC Cancer 2006, 6:126 http://www.biomedcentral.com/1471-2407/6/126
Page 4 of 6
(page number not for citation purposes)
results from increasing genetic disarray accumulated over
the time. Therefore carcinogenesis is multistep and age
dependent process [20]. The multiple mechanisms and
multiple players involved in this process inspired us to
evaluate the status of most commonly disrupted genes i.e.
p53 and c-erbB-2 specifically the simultaneous over
expression of these genes in gallbladder diseases in the
same individual.
There is no literature available on p53 and c-erbB-2 study
in gallbladder diseases in Indian patients except one [21].
Our region (Northern India) being the endemic to GBC,
this pilot study was conducted to recognize the over
expression of p53 protein and c-erbB-2 protein in gall-
bladder diseases. So it could be correlated with age, sex,
stage, grade and lymph node status especially in GBC.
This will help in developing the better therapeutic strate-
gies for GBC.
Present study showed only 20% p53 positivity in GBC
compared to the higher figures reported by other workers
[15,22-24] and no p53 over expression either in premalig-
nant condition or in GSD patients.
The role of p53 seems to be limited in the initiation of
gallbladder carcinogenesis as none of the premalignant
lesions and grade I GBC showed p53 over expression. The
higher p53 over expression with the increasing grade of
GBC suggests its role in tumour progression rather than
initiation. It seems that the c-erbB-2 gene alteration is an
early event and plays a critical role in gallbladder carcino-
genesis as nearly 35% of grade I and 40% of adenoma
showed c-erbB-2 over expression in our population.
Increasing over expression of p53 with the increasing
grade of the tumour and decreasing over expression of c-
erbB-2 with increasing grade suggest that c-erbB-2 is likely
to play a lesser role in tumour progression in comparison
to the p53 gene.
We have taken all the intense c-erbB-2 membranous stain-
ing as a positive staining in well to moderately differenti-
ated cases whereas cytoplasmic staining in few poorly
differentiated cases were also regarded as a positive stain-
ing. This result is very well supported by few studies
[25,26] where cytoplasmic positivity along with membra-
nous staining was regarded as positive.
Photomicrograph showing both c-erbB-2 and p53 staining Figure 3
Photomicrograph showing both c-erbB-2 and p53 staining. 
(Figure 3a and b): apical granular and intense membranous c-
erbb-2 positivity in adenoma gallbladder; (c and d): strong 
nuclear p53 positivity in well differentiated and poorly differ-
entiated adenocarcinoma respectively.
Table 3: Correlation of p 53 expression with the grade of 
tumour
Patient Group P53 expression χ2 P value
(No. of cases) (+) (-)
Grade I (14) 0 14 6.568 0.037
Grade II (10) 2 8
Grade III (16) 6 10
Table 2: Correlation of p53 expression with the stage of tumour
Patient Group P53 expression χ2 P value
(No. of cases) (+) (-)
Stage I (0) 0 0 0.208 NS
Stage II (8) 2 6
Stage III (12) 2 10
Stage IV (20) 4 16
Photomicrograph showing c-erbB-2 staining Figure 2
Photomicrograph showing c-erbB-2 staining. (Fig 2b and d) 
patchy and membranous positivity in well differentiated carci-
noma; (2a) in moderately differentiated carcinoma; (2c) cyto-
plasmic and membranous in poorly differentiated carcinomaBMC Cancer 2006, 6:126 http://www.biomedcentral.com/1471-2407/6/126
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The c-erbB-2 over expression in papillary-adenoma in our
results substantiates the evidence of adenoma-carcinoma
sequence [27]. This is further supported by other recent
studies [11,28]. In comparison to the other studies regard-
ing the p53 and c-erbB-2 over expression percentage, our
study revealed lower percentage of positivity. This dispar-
ity could be due to differences in genetic predisposition
between the two populations, further study is required to
establish it. There was no correlation of p53 over expres-
sion with the age and sex of the patient while c-erbB-2 was
over expressed in younger age group patients, again indi-
cating its role as an early event in carcinogenesis of gall-
bladder.
We have not found the co expression of c-erbB-2 and p53
in GBC except in one case of poorly differentiated carci-
noma and that too showing weak positivity. This observa-
tion suggests the lack of cooperation between p53 and c-
erbB-2 gene in neoplastic transformation of gallbladder.
This finding is very well supported by Kim et al, 2001 [5].
Conclusion
Both p53 and c-erbB-2 might play an independent role in
gallbladder carcinogenesis. c-erbB-2 seems to play critical
role in tumour initiation and p53 in the tumour progres-
sion. So cerbB-2 may be used as an important marker to
identify the premalignant lesions which are likely to
progress into malignancy. However further study with a
big sample size is required to validate the results.
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